Dean Ho
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Dean Ho has a total of 96 co-authors. Here are the top co-authors by number of shared publications:
Dong-Keun Lee
Division of Oral Biology and Medicine, School of Dentistry, University of California, Los Angeles, CA 90095
6 shared publications- Edward Kai-Hua Chow
Department of Biomedical Engineering, College of Design and Engineering, National University of Singapore, Singapore
6 shared publications - Laura Moore
Hospital for Special Surgery/Cornell Medical Center Program
5 shared publications Eiji Osawa
NanoCarbon Research Institute, Shinshu University, Ueda, Nagano 386-8567, Japan
4 shared publicationsHan B. Man
Department of Mechanical Engineering, Robert R. McCormick School of Engineering and Applied Science, Northwestern University, Evanston, IL, USA
4 shared publicationsTheodore Kee
National University of Singapore
4 shared publications
Latest Publications
- Open Access
- 13 November 2018
- Published by Springer Nature
- p. 319-344
Engineering Multifunctional Nanomedicine Platforms for Drug Delivery and Imaging
- 13 November 2018
- Published by Springer Nature
- p. 319-344
Open AccessEngineering Multifunctional Nanomedicine Platforms for Drug Delivery and Imaging
- 23 October 2017
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 114 (45) , E9445-E9454
Clinical validation of a nanodiamond-embedded thermoplastic biomaterial
Significance: There is a continued need to advance novel nanomedicine platforms into the clinic to address treatment challenges in oncology, infection, and regenerative medicine, among other areas. As such, this work demonstrates the in-human validation of nanodiamonds through their incorporation into gutta percha [nanodiamond-embedded gutta percha (NDGP)], a polymer that repairs root canal treatment sites following tissue disinfection. A randomized, dual-arm clinical trial was implemented, and study endpoints included confirmation of lesion healing, postoperative pain reduction, and the absence of reinfection. To date, the NDGP-treated patients successfully met the study endpoints. Therefore, these findings support the potential expansion of nanodiamonds, and the broader nanomedicine field, into other disease indications.
- 23 October 2017
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 114 (45) , E9445-E9454
Clinical validation of a nanodiamond-embedded thermoplastic biomaterial
Significance: There is a continued need to advance novel nanomedicine platforms into the clinic to address treatment challenges in oncology, infection, and regenerative medicine, among other areas. As such, this work demonstrates the in-human validation of nanodiamonds through their incorporation into gutta percha [nanodiamond-embedded gutta percha (NDGP)], a polymer that repairs root canal treatment sites following tissue disinfection. A randomized, dual-arm clinical trial was implemented, and study endpoints included confirmation of lesion healing, postoperative pain reduction, and the absence of reinfection. To date, the NDGP-treated patients successfully met the study endpoints. Therefore, these findings support the potential expansion of nanodiamonds, and the broader nanomedicine field, into other disease indications.
- Open Access
- 1 June 2017
- Published by Elsevier in SLAS Technology
- Vol. 22 (3) , 231-232
Making N-of-1 Medicine a Reality
- 1 June 2017
- Published by Elsevier in SLAS Technology
- Vol. 22 (3) , 231-232
Open AccessMaking N-of-1 Medicine a Reality
- Open Access
- 1 June 2017
- Published by Elsevier in SLAS Technology
- Vol. 22 (3) , 276-288
Optimizing Combination Therapy for Acute Lymphoblastic Leukemia Using a Phenotypic Personalized Medicine Digital Health Platform: Retrospective Optimization Individualizes Patient Regimens to Maximize Efficacy and Safety
- 1 June 2017
- Published by Elsevier in SLAS Technology
- Vol. 22 (3) , 276-288
Open AccessOptimizing Combination Therapy for Acute Lymphoblastic Leukemia Using a Phenotypic Personalized Medicine Digital Health Platform: Retrospective Optimization Individualizes Patient Regimens to Maximize Efficacy and Safety
- 10 November 2016
- Published by American Chemical Society (ACS) in Nano Letters
- Vol. 16 (12) , 7551-7564
Nanodiamond–Gadolinium(III) Aggregates for Tracking Cancer Growth In Vivo at High Field
The ability to track labeled cancer cells in vivo would allow researchers to study their distribution, growth, and metastatic potential within the intact organism. Magnetic resonance (MR) imaging is invaluable for tracking cancer cells in vivo as it benefits from high spatial resolution and the absence of ionizing radiation. However, many MR contrast agents (CAs) required to label cells either do not significantly accumulate in cells or are not biologically compatible for translational studies. We have developed carbon-based nanodiamond–gadolinium(III) aggregates (NDG) for MR imaging that demonstrated remarkable properties for cell tracking in vivo. First, NDG had high relaxivity independent of field strength, a finding unprecedented for gadolinium(III) [Gd(III)]–nanoparticle conjugates. Second, NDG demonstrated a 300-fold increase in the cellular delivery of Gd(III) compared to that of clinical Gd(III) chelates without sacrificing biocompatibility. Further, we were able to monitor the tumor growth of NDG-labeled flank tumors by T1- and T2-weighted MR imaging for 26 days in vivo, longer than was reported for other MR CAs or nuclear agents. Finally, by utilizing quantitative maps of relaxation times, we were able to describe tumor morphology and heterogeneity (corroborated by histological analysis), which would not be possible with competing molecular imaging modalities.
- 10 November 2016
- Published by American Chemical Society (ACS) in Nano Letters
- Vol. 16 (12) , 7551-7564
Nanodiamond–Gadolinium(III) Aggregates for Tracking Cancer Growth In Vivo at High Field
The ability to track labeled cancer cells in vivo would allow researchers to study their distribution, growth, and metastatic potential within the intact organism. Magnetic resonance (MR) imaging is invaluable for tracking cancer cells in vivo as it benefits from high spatial resolution and the absence of ionizing radiation. However, many MR contrast agents (CAs) required to label cells either do not significantly accumulate in cells or are not biologically compatible for translational studies. We have developed carbon-based nanodiamond–gadolinium(III) aggregates (NDG) for MR imaging that demonstrated remarkable properties for cell tracking in vivo. First, NDG had high relaxivity independent of field strength, a finding unprecedented for gadolinium(III) [Gd(III)]–nanoparticle conjugates. Second, NDG demonstrated a 300-fold increase in the cellular delivery of Gd(III) compared to that of clinical Gd(III) chelates without sacrificing biocompatibility. Further, we were able to monitor the tumor growth of NDG-labeled flank tumors by T1- and T2-weighted MR imaging for 26 days in vivo, longer than was reported for other MR CAs or nuclear agents. Finally, by utilizing quantitative maps of relaxation times, we were able to describe tumor morphology and heterogeneity (corroborated by histological analysis), which would not be possible with competing molecular imaging modalities.
- 28 September 2016
- Published by American Chemical Society (ACS)
- Vol. 10 (10) , 9087-9092
Diamonds, Digital Health, and Drug Development: Optimizing Combinatorial Nanomedicine
The field of nanomedicine has already seen substantial progress in the clinic, with multiple formulations being evaluated through clinical studies. From poly(lactic-co-glycolic acid) and cyclodextrin-based drug-delivery platforms to metallic nanoparticles for photothermal treatment and imaging, nanotechnology has enabled versatile strategies to treat and to diagnose a wide range of disorders. However, as the field as a whole pushes forward, barriers that have always challenged conventional drug development have already started to impact nanomedicine translation. These include exorbitant costs, substantial time to development, and the uncertainty of achieving major improvements in efficacy or safety. Of note, there has been, until recent advances, a virtual inability to identify optimal drug doses either as monotherapies or components of combination therapy. In this Nano Focus, we assess how the impact of nanotechnology in the clinic can be optimized through systematically designed combinatorial nanotherapy. In addition, we provide a clinical perspective on how a recently unveiled technology platform can substantially alter the landscape of combinatorial nanomedicine, drug development, as well as conventional drug development.
- 28 September 2016
- Published by American Chemical Society (ACS)
- Vol. 10 (10) , 9087-9092
Diamonds, Digital Health, and Drug Development: Optimizing Combinatorial Nanomedicine
The field of nanomedicine has already seen substantial progress in the clinic, with multiple formulations being evaluated through clinical studies. From poly(lactic-co-glycolic acid) and cyclodextrin-based drug-delivery platforms to metallic nanoparticles for photothermal treatment and imaging, nanotechnology has enabled versatile strategies to treat and to diagnose a wide range of disorders. However, as the field as a whole pushes forward, barriers that have always challenged conventional drug development have already started to impact nanomedicine translation. These include exorbitant costs, substantial time to development, and the uncertainty of achieving major improvements in efficacy or safety. Of note, there has been, until recent advances, a virtual inability to identify optimal drug doses either as monotherapies or components of combination therapy. In this Nano Focus, we assess how the impact of nanotechnology in the clinic can be optimized through systematically designed combinatorial nanotherapy. In addition, we provide a clinical perspective on how a recently unveiled technology platform can substantially alter the landscape of combinatorial nanomedicine, drug development, as well as conventional drug development.
- 6 April 2016
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 8 (333) , 333ra49
Individualizing liver transplant immunosuppression using a phenotypic personalized medicine platform
Postoperative liver transplant immunosuppression was personalized using a phenotypic, disease mechanism–independent and indication-agnostic approach.
- 6 April 2016
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 8 (333) , 333ra49
Individualizing liver transplant immunosuppression using a phenotypic personalized medicine platform
Postoperative liver transplant immunosuppression was personalized using a phenotypic, disease mechanism–independent and indication-agnostic approach.
- 3 February 2016
- Published by Royal Society of Chemistry (RSC) in Nanoscale
- Vol. 8 (7) , 4267-4275
Combinatorial release of dexamethasone and amiodarone from a nano-structured parylene-C film to reduce perioperative inflammation and atrial fibrillation
Suppressing perioperative inflammation and post-operative atrial fibrillation requires effective drug delivery platforms (DDP). Localized anti-inflammatory and anti-arrhythmic agent release may be more effective than intravenous treatment to improve patient outcomes. This study utilized a dexamethasone (DEX) and amiodarone (AMIO)-loaded Parylene-C (PPX) nano-structured film to inhibit inflammation and atrial fibrillation. The PPX film was tested in an established pericardial adhesion rabbit model. Following sternotomy, the anterior pericardium was resected and the epicardium was abraded. Rabbits were randomly assigned to five treatment groups: control, oxidized PPX (PPX-Oxd), PPX-Oxd infused with DEX (PPX-Oxd[DEX]), native PPX (PPX), and PPX infused with DEX and AMIO (PPX[AMIO, DEX]). 4 weeks post-sternotomy, pericardial adhesions were evaluated for gross adhesions using a 4-point grading system and histological evaluation for epicardial neotissue fibrosis (NTF). Atrial fibrillation duration and time per induction were measured. The PPX[AMIO, DEX] group had a significant reduction in mean adhesion score compared with the control group (control 2.75 ± 0.42 vs. PPX[AMIO, DEX] 0.25 ± 0.42, P < 0.001). The PPX[AMIO, DEX] group was similar to native PPX (PPX 0.38 ± 0.48 vs. PPX[AMIO, DEX] 0.25 ± 0.42, PNS). PPX-Oxd group adhesions were indistinguishable from controls (PPX-Oxd 2.83 ± 0.41 vs. control 2.75 ± 0.42, PNS). NTF was reduced in the PPX[AMIO, DEX] group (0.80 ± 0.10 mm) compared to control (1.78 ± 0.13 mm, P < 0.001). Total duration of atrial fibrillation was decreased in rabbits with PPX[AMIO, DEX] films compared to control (9.5 ± 6.8 s vs. 187.6 ± 174.7 s, p = 0.003). Time of atrial fibrillation per successful induction decreased among PPX[AMIO, DEX] films compared to control (2.8 ± 1.2 s vs. 103.2 ± 178 s, p = 0.004). DEX/AMIO-loaded PPX films are associated with reduced perioperative inflammation and a diminished atrial fibrillation duration. Epicardial application of AMIO, DEX films is a promising strategy to prevent post-operative cardiac complications.
- 3 February 2016
- Published by Royal Society of Chemistry (RSC) in Nanoscale
- Vol. 8 (7) , 4267-4275
Combinatorial release of dexamethasone and amiodarone from a nano-structured parylene-C film to reduce perioperative inflammation and atrial fibrillation
Suppressing perioperative inflammation and post-operative atrial fibrillation requires effective drug delivery platforms (DDP). Localized anti-inflammatory and anti-arrhythmic agent release may be more effective than intravenous treatment to improve patient outcomes. This study utilized a dexamethasone (DEX) and amiodarone (AMIO)-loaded Parylene-C (PPX) nano-structured film to inhibit inflammation and atrial fibrillation. The PPX film was tested in an established pericardial adhesion rabbit model. Following sternotomy, the anterior pericardium was resected and the epicardium was abraded. Rabbits were randomly assigned to five treatment groups: control, oxidized PPX (PPX-Oxd), PPX-Oxd infused with DEX (PPX-Oxd[DEX]), native PPX (PPX), and PPX infused with DEX and AMIO (PPX[AMIO, DEX]). 4 weeks post-sternotomy, pericardial adhesions were evaluated for gross adhesions using a 4-point grading system and histological evaluation for epicardial neotissue fibrosis (NTF). Atrial fibrillation duration and time per induction were measured. The PPX[AMIO, DEX] group had a significant reduction in mean adhesion score compared with the control group (control 2.75 ± 0.42 vs. PPX[AMIO, DEX] 0.25 ± 0.42, P < 0.001). The PPX[AMIO, DEX] group was similar to native PPX (PPX 0.38 ± 0.48 vs. PPX[AMIO, DEX] 0.25 ± 0.42, PNS). PPX-Oxd group adhesions were indistinguishable from controls (PPX-Oxd 2.83 ± 0.41 vs. control 2.75 ± 0.42, PNS). NTF was reduced in the PPX[AMIO, DEX] group (0.80 ± 0.10 mm) compared to control (1.78 ± 0.13 mm, P < 0.001). Total duration of atrial fibrillation was decreased in rabbits with PPX[AMIO, DEX] films compared to control (9.5 ± 6.8 s vs. 187.6 ± 174.7 s, p = 0.003). Time of atrial fibrillation per successful induction decreased among PPX[AMIO, DEX] films compared to control (2.8 ± 1.2 s vs. 103.2 ± 178 s, p = 0.004). DEX/AMIO-loaded PPX films are associated with reduced perioperative inflammation and a diminished atrial fibrillation duration. Epicardial application of AMIO, DEX films is a promising strategy to prevent post-operative cardiac complications.
- Open Access
- 7 August 2015
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 1 (7) , e1500439
Nanodiamonds: The intersection of nanotechnology, drug development, and personalized medicine
A method of developing new cancer therapies with nanodiamonds.
- 7 August 2015
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 1 (7) , e1500439
Open AccessNanodiamonds: The intersection of nanotechnology, drug development, and personalized medicine
A method of developing new cancer therapies with nanodiamonds.
- 21 April 2015
- Published by Springer Nature
- Vol. 166, 85-102
Nanodiamond-Based Chemotherapy and Imaging
The advent of cancer nanomedicine has forged new pathways for the enhanced imaging and treatment of a broad range of cancers using new classes of materials. Among the many platforms being developed for drug delivery and imaging, nanodiamonds (NDs) possess several important attributes that may be beneficial toward improving the efficacy and safety of cancer nanomedicine applications. These include the uniquely faceted surfaces of the ND particles that result in electrostatic properties that mediate enhanced interactions with water and loaded therapeutic compounds, scalable processing and synthesis parameters, versatility as platform carriers, and a spectrum of other characteristics. In addition, comprehensive in vitro and in vivo studies have demonstrated that NDs are well tolerated. This chapter will examine several recent studies that have harnessed the ND agent as a foundation for both systemic and localized drug delivery, as well as the marked improvements in magnetic resonance imaging efficiency that has been observed following ND-contrast agent conjugation. In addition, insight into the important steps toward bringing the ND translational pathway to the clinic will be discussed.
- 21 April 2015
- Published by Springer Nature
- Vol. 166, 85-102
Nanodiamond-Based Chemotherapy and Imaging
The advent of cancer nanomedicine has forged new pathways for the enhanced imaging and treatment of a broad range of cancers using new classes of materials. Among the many platforms being developed for drug delivery and imaging, nanodiamonds (NDs) possess several important attributes that may be beneficial toward improving the efficacy and safety of cancer nanomedicine applications. These include the uniquely faceted surfaces of the ND particles that result in electrostatic properties that mediate enhanced interactions with water and loaded therapeutic compounds, scalable processing and synthesis parameters, versatility as platform carriers, and a spectrum of other characteristics. In addition, comprehensive in vitro and in vivo studies have demonstrated that NDs are well tolerated. This chapter will examine several recent studies that have harnessed the ND agent as a foundation for both systemic and localized drug delivery, as well as the marked improvements in magnetic resonance imaging efficiency that has been observed following ND-contrast agent conjugation. In addition, insight into the important steps toward bringing the ND translational pathway to the clinic will be discussed.